GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GeneDx Holdings Corp (NAS:WGS) » Definitions » Cash Flow from Investing

GeneDx Holdings (GeneDx Holdings) Cash Flow from Investing : $-43.7 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is GeneDx Holdings Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, GeneDx Holdings spent $2.4 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $2.5 Mil for other investing activities. In all, GeneDx Holdings spent $4.9 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


GeneDx Holdings Cash Flow from Investing Historical Data

The historical data trend for GeneDx Holdings's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneDx Holdings Cash Flow from Investing Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
-15.46 -31.97 -20.79 -141.33 -43.73

GeneDx Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.84 -0.46 -11.27 -27.13 -4.86

GeneDx Holdings Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

GeneDx Holdings's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

GeneDx Holdings's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneDx Holdings  (NAS:WGS) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

GeneDx Holdings's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-2.4 Mil. It means GeneDx Holdings spent $2.4 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

GeneDx Holdings's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.0 Mil. It means GeneDx Holdings gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

GeneDx Holdings's purchase of business for the three months ended in Dec. 2023 was $0.0 Mil. It means GeneDx Holdings spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

GeneDx Holdings's sale of business for the three months ended in Dec. 2023 was $0.0 Mil. It means GeneDx Holdings gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

GeneDx Holdings's purchase of investment for the three months ended in Dec. 2023 was $0.0 Mil. It means GeneDx Holdings spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

GeneDx Holdings's sale of investment for the three months ended in Dec. 2023 was $0.0 Mil. It means GeneDx Holdings gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

GeneDx Holdings's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.0 Mil. It means GeneDx Holdings paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

GeneDx Holdings's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.0 Mil. It means GeneDx Holdings paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

GeneDx Holdings's cash from other investing activities for the three months ended in Dec. 2023 was $-2.5 Mil. It means GeneDx Holdings paid $2.5 Mil for other investing activities.


GeneDx Holdings Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of GeneDx Holdings's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneDx Holdings (GeneDx Holdings) Business Description

Traded in Other Exchanges
N/A
Address
333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx and Legacy Sema4 diagnostics.
Executives
Kareem Saad officer: Chief Business Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Katherine Stueland director, officer: Chief Executive Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Kevin Feeley officer: Chief Financial Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Keith A. Meister director, 10 percent owner C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Karen Ann White officer: Chief People Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Casdin Partners Fo1-msv, Lp director, 10 percent owner C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Corvex Management Lp director, 10 percent owner 667 MADISON AVENUE, NEW YORK NY 10065
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137